Link Immunotherapeutics

Link Immunotherapeutics Develops Next-Generation T Cell Engager Therapies Aimed at Treating a Wide Range of Tumor Indications. The Company Designs Novel, Highly Developable Immunotherapies with Greater Selectivity for Tumors Over Normal Tissues, More Complete T Cell Activation, Offering Patients Enhanced Safety and More Durable Cancer Responses.